Michael DiFiore

Rami Katkhuda

Jin Law

Matthew Caufield

Annabel Samimy

Mohit Bansal

Seamus Fernandez

Alice

Alice Nettleton

Colleen Garvey

Dennis Ding

Jayed Momin

Richard Law

Sadia Rahman

- Mineralys Therapeutics (MLYS) has achieved **successful clinical outcomes** for its pivotal program of **lorundrostat** in hyperaldosteronism-driven, uncontrolled and resistant hypertension, with **12-month data approaching** and preparations for **FDA filing and commercial launch** underway.  **[1933414_2162677_0]** **[1933414_2162677_1]** 
- Lorundrostat is initially targeting the **fourth-line hypertension market**, with plans to expand to third-line, representing a potential **20 million patients** in the U.S. across both lines.  **[1933414_2162677_1]** **[1933414_2162677_2]** 
- The company views lorundrostat as having a **superior profile** compared to competitors like Baqsrostat, with a recent survey indicating **two-thirds of physicians prefer lorundrostat**.  **[1933414_2162677_3]** **[1933414_2162677_4]** 
- Mineralys is actively pursuing **partnerships** for commercialization to maximize opportunity, while also noting that an independent launch targeting the **60,000 key prescribers** is manageable.  **[1933414_2162677_4]** 
- Additional clinical data for obstructive sleep apnea (OSA) in hypertension patients is **expected in Q1 2026**.  **[1933414_2162677_1]** **[1933414_2162677_2]**

Mineralys Therapeutics Nears Lorundrostat Commercial Launch and FDA Filing

- Mineralys Therapeutics announced the pricing of an **upsized underwritten public offering** of **9,803,921 shares** of its common stock at **$25.50 per share** on September 2, 2025.  **[1933414_0001933414-25-000120_exhibit992-8xkseptember2025.htm:0]** 
- The offering is expected to generate approximately **$250.0 million** in gross proceeds  **[1933414_0001933414-25-000120_exhibit992-8xkseptember2025.htm:0]**  and **$234.7 million** in net proceeds for the company.  **[1933414_0001933414-25-000120_mlys-20250902.htm:1]** 
- Mineralys has granted underwriters a 30-day option to purchase up to an additional **1,470,588 shares**, which could increase net proceeds to approximately **$269.9 million** if fully exercised.  **[1933414_0001933414-25-000120_exhibit992-8xkseptember2025.htm:0]** **[1933414_0001933414-25-000120_mlys-20250902.htm:1]** 
- The net proceeds will be used to fund clinical development of **lorundrostat**, including research and development and manufacturing, pre-commercialization activities, working capital, and general corporate purposes.  **[1933414_0001933414-25-000120_exhibit991-8xkseptember2025.htm:0]** **[1933414_0001933414-25-000120_exhibit992-8xkseptember2025.htm:0]** 
- The offering is expected to close on or about **September 4, 2025**.  **[1933414_0001933414-25-000120_exhibit992-8xkseptember2025.htm:0]** **[1933414_0001933414-25-000120_mlys-20250902.htm:1]**

Mineralys Therapeutics Prices Upsized Public Offering